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Abstract
Activin A is expressed in endocrine precursor cells of the fetal pancreatic anlage. To determine the physiological
significance of activins in the pancreas, a transgenic mouse line expressing the truncated type II activin receptor under the
control of L-actin promoter was developed. Histological analyses of the pancreas revealed that the pancreatic islets of the
transgenic mouse were small in size and were located mainly along the pancreatic ducts. Immunoreactive insulin was detected
in islets, some acinar cells, and in some epithelial cells in the duct. In addition, there were abnormal endocrine cells outside
the islets. The shape and the size of the endocrine cells varied and some of them were larger than islets. These cells expressed
immunoreactive insulin and glucagon. In the exocrine portion, there were morphologically abnormal exocrine cells, which
did not form a typical acinar structure. The cells lacked spatial polarity characteristics of acinar cells but expressed
immunoreactive amylase, which was distributed diffusely in the cytoplasm. Plasma glucose concentration was normal in the
transgenic mouse before and after the administration of glucose. The insulin content of the pancreas in transgenic and
normal mice was nearly identical. These results suggest that activins or related ligands regulate the differentiation of the
pancreatic endocrine and exocrine cells. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The members of the transforming growth factor
(TGF)-L supergene family regulate cell proliferation,
di¡erentiation, morphogenesis and tissue remodeling
(for reviews see [1^3]). Activins belong to this super-
family and elicit diverse e¡ects in various cell systems
[4,5]. In amphibians, activins and related factors are
thought to be a regulator of mesoderm induction [6^
10]. They induce mesoderm of a dorsoanterior nature
in Xenopus explants. They also modulate the forma-
tion of neural tissue [11,12]. Despite the importance
of activins in the regulation of development in am-
phibians, the role of activins in the development of
mammalians is less clear. In the mouse embryonic
stem cells, activin A is shown to induce the forma-
tion of dorsoanterior-like mesoderm [13]. Mutant
mice lacking genes encoding activin subunits were
developed. Activin LA-de¢cient mice develop to
term but die within 24 h of birth. They lack whiskers
and lower incisors and have abnormalities in cranio-
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facial development [14]. Mice lacking the activin LB
subunit have an apparent failure of eyelid fusion [15].
Mice de¢cient in both activin LA and LB subunits
showed the defects of both individual mutants [15].
On the other hand, mutant mice lacking the type II
activin receptor have suppressed follicle-stimulating
hormone secretion and defects in reproductive per-
formance [16]. Mutant mice lacking the type IIB ac-
tivin receptor have severe anomalies in the cardiovas-
cular system [17]. Given that activins are expressed in
various organs [18] and are considered to regulate
various cellular functions, abnormalities found in
these mutant mice were fewer than expected. This
may be due at least partly to the existence of multiple
subunits of activin [19^21], multiple subtypes of ac-
tivin receptors [22^24] and other possible reasons in-
cluding maternal delivery of activins.
In the pancreas, activin A is expressed in endocrine
cells of the islets [25] and is expressed during devel-
opment [26]. In particular, activin A is expressed in
the endocrine precursor cells of the pancreatic anlage
[26]. Since activin A is capable of converting amy-
lase-secreting pancreatic AR42J cells into endocrine
cells [27], it is possible that activin A modulates the
di¡erentiation of pancreatic endocrine cells in vivo.
To clarify the role of activins in the pancreas, we
generated transgenic mice expressing truncated type
II activin receptors (tActRII). The tActRII acts as a
dominantly negative form of the activin receptor sys-
tem [11,28] and blocks the action of activins and
related factors. These transgenic mice had various
abnormalities of the pancreas.
2. Materials and methods
2.1. Transgene construct
A 0.5 kb fragment of tActRII cDNA was linked to
cytomegalovirus enhancer and chicken-L-actin pro-
moter (Fig. 1). A 2.9 kb fragment that contained
rabbit L-globin gene, SV40 polyA, was isolated
from plasmid vector by digestion with SalI and
PstI site.
2.2. PCR analysis
The presence of transgene in the founders and
their progeny was con¢rmed by polymerase chain
reaction (PCR) typing of tail DNA using primers
speci¢c for human type II activin receptor sequence
5P-TTCTCCGGCGCCTCGGGAAA-3P and rabbit
L-actin sequence 5P-GTGGTATTTGTGAGCCAG-
GG. For PCR, 50 Wl of the reaction mixture (con-
taining PCR bu¡er, 1.5 mM MgCl2, 0.2 mM dNTP
mix, 0.5 WM each of the two primers, 2.5 U Taq
polymerase) was added to the microfuge tube, and
then subjected to 30 PCR cycles. In each cycle, sam-
ples were heated at 94‡C for 45 s to denature DNA,
cooled to 68‡C for 45 s to anneal the primers and
heated at 72‡C for 45 s to activate the polymerase.
The reaction mixture was then electrophoresed in
2.0% agarose gel. The band of transgene was de-
tected at 550 base pairs.
2.3. Generation and screening of transgenic mice
B6C3F1 hybrid (females; approximately 8 weeks
of age), C57BL/6N (males; approximately 8 weeks
of age), ICR (females; approximately 8 weeks of
age) mice were obtained from Charles River Japan
(Tokyo, Japan). Embryos at the 1-cell stage were
isolated from super ovulated B6C3F1 females mated
to C57BL/6N males. Transgenic mice were generated
by pronuclear microinjection of the DNA construct
at a concentration of approximately 2 ng/Wl in PBS
at pH 7.4. Embryos surviving the injection were re-
implanted into pseudopregnant ICR foster mothers
and allowed to develop to term. After the mice had
been weaned, total genomic DNA was isolated from
a part of the tail to test for the presence of the trans-
gene construct by Southern blot hybridization and
by PCR analysis.
2.4. Northern blot analysis
Total RNA was obtained by the guanidinium thio-
cyanate method. RNA yields were estimated from
the absorbance at 260 nm. Ten Wg of RNA was
fractionated on 1.0% agarose formamide gels and
blotted onto nylon membrane. The membrane was
prehybridized at 42‡C for 2 h in a medium
(5USSC, 1.0% SDS, 5UDenhardt’s solution, 50%
formamide and 0.5 mg/ml of denatured salmon
sperm DNA) before adding the 32P-labeled tActRII
cDNA probe. The membrane was hybridized at 42‡C
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overnight and washed in 2USSC, 0.1% SDS solution
for 10 min, then exposed to X-ray overnight.
2.5. Histochemistry and immunocytochemistry
Tissues were ¢xed in 4% (wt/vol) paraformalde-
hyde or 10% (v/v) formalin. Standard techniques
were used for embedding, sectioning and staining
of tissues. Immunocytochemistry was done as de-
scribed previously [25]. Antibodies against insulin
and glucagon were provided by Dr. Wakabayashi
of Biosignal Research Center, Gunma University.
Anti-activin A antibody, provided by Dr. Y. Eto of
the Central Research Laboratory, Ajinomoto Inc.
(Kawasaki, Japan), cross-reacts with both LA dimer
and LA monomer but not with either inhibin A or
follistatin-bound activin A [25]. Antibody against
CD68 was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA) and anti-myoglobin
antibody was from Daco (Glostrup, Denmark). To
compare the size of islets in normal and transgenic
pancreas, we measured the diameter of islets. When
the islet was oval, the mean of the major and minor
axes was calculated. We also measured the distance
between the margin of an islet and its nearest duc-
tule. The area of islets and exocrine tissue was meas-
ured by using a computer program ‘Photoshop’.
2.6. Glucose tolerance test
After overnight fasting, 1 g/kg of glucose dissolved
in physiological saline was administered intraperito-
neally. At 0, 30, 60, 90 and 120 min after the admin-
istration of glucose, blood glucose concentration was
measured by the glucose oxides method. Plasma in-
sulin concentration was measured as described pre-
viously [27]. Statistical analysis was done by Stu-
dent’s t-test.
3. Results
A transgene was constructed by fusing a kinase-
deleted human ActRII cDNA downstream of the
human L-actin promoter (LA-tActRII) (Fig. 1). We
have previously shown that mutated human ActRII
lacking kinase activity blocks activin receptor signal-
ing by forming non-functional oligomers with wild-
type mouse ActRI that binds the same ligand [28].
The L-actin promoter was chosen because it directs a
high level of transgene [29]. Expression of this trans-
gene should inhibit activin receptor signaling.
Of 47 potential transgenic founder mice born, sev-
en carried the transgene. All of them were born alive
and appeared relatively well. They were phenotypi-
cally normal except that many of them lacked
whiskers and reached adulthood. Five of them were
female and two were male. Female founders were
infertile. Two male founders were fertile and two
transgenic lines were generated (S19 and S2). In the
S19 mouse line, the intact LA-tActRII transgene was
stably integrated at a single site containing three cop-
ies per haploid genome and transmitted in typical
Mendelian fashion. The S19 line of LA-tActRII
transgenic mice actively expressed human tActRII
RNA. Total RNA was isolated from representative
Fig. 1. Transgene construct. Schematic presentation of the LA-tActRII is shown. The tActRII was produced by PCR, which retained
the extracellular domain and transmembrane domain but deleted most of the intracellular domain.
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tissues of the transgenic line and analyzed by North-
ern blotting using a human ActRII speci¢c probe.
The transgene was transcribed in a wide variety of
tissues including the pancreas (data not shown).
The S19 transgenic mice were apparently normal
except that approximately 50% of them lacked
whiskers. They grew normally but female mice were
infertile although histological abnormality was not
found in the ovary. Histological analyses were done
in the transgenic mice aging 2 to 5 months. The size
and the wet weight of the pancreas in the transgenic
mice were nearly identical to those in normal mice.
Histological analyses of the pancreas of the trans-
genic mice revealed that most of the pancreatic islets
were small and located in the vicinity of the pancre-
atic ducts (Fig. 2A). In normal mice, the mean diam-
eter of islets was 235 Wm (n = 495 from 10 mice) and
the diameter was less than 100 Wm in only 11% of the
islets (Fig. 3). In the transgenic mice, the mean diam-
eter of islets was 76 Wm (n = 426 from 8 mice). In
64% of the islets, the diameter was less than 100
Wm (Fig. 3). In normal mice, the distance from mar-
gin of islet to the nearest ductule was less than 200
Wm in 32% of the islets whereas, in the transgenic
mice, it was less than 200 Wm in 87% of the islets.
In some islets of the transgenic mice, the distribution
of the islet cells and staining of nuclei were irregular
(Fig. 2B). This was partly due to the inclusion of a
ductule in the islet. In¢ltration of mononuclear cells
was occasionally found in connective tissues sur-
rounding the pancreatic duct (Fig. 2C). These cells
were lymphocytes since they expressed CD3, a
marker of T lymphocytes (data not shown). Immu-
nocytochemistry using anti-insulin antibody showed
that, as in islets of normal mice, the positive immu-
noreactivity was found in the core of small pancre-
atic islets (Fig. 4A). In addition, it was detected in
some portions of the small acini which are located
near the pancreatic duct. Immunoreactive insulin was
also found in some cells of the pancreatic duct (Fig.
4A). Similarly, immunoreactive glucagon (Fig. 4B)
was observed in the ductal epithelial cells. Note
that cells expressing both glucagon and insulin were
not observed in the pancreatic duct. Interestingly,
cells morphologically di¡erent from either acinar or
islet cells were observed among acini (Fig. 5A,B).
The shapes of the cells were quite variable. Some
were polygonal whereas others extended processes
and connected each other. Under light microscopy,
some of them appeared to be syncytial multi-
nucleated cells (Fig. 5A). Numerous number of nu-
clei were distributed irregularly and were often clus-
tered in the cells. The sizes of the cells were quite
variable and some of them were greater than that
of islets in the transgenic mice. These cells were pos-
itively stained with anti-insulin antibody (Fig. 6A).
Immunoreactive glucagon was also detected in the
cells (Fig. 6B). Hence, the multinucleated cells were
double-positive cells expressing insulin and glucagon.
Immunoreactivities of insulin and glucagon were de-
tected throughout the cell body and were particularly
strong in some compartments. These multinucleated
cells were not macrophages since they did not express
Fig. 3. Comparison of the size of islets in normal and transgen-
ic mice. The diameter of islets was measured in normal (E) and
transgenic (F) mice. The numbers of islets examined in normal
and transgenic mice were 495 and 426, respectively.
Fig. 2. Histological analysis of the pancreas of the transgenic mouse. (A) Hematoxylin^eosin (HpE)-stained section of pancreas from
4-month-old transgenic (TG) and normal (N) mice (100U). (B) HpE-stained section of pancreas from 4-month-old transgenic (TG)
and normal (N) mice (400U). Arrows indicate irregular distribution of islet cells. (C) HpE-stained section of pancreas from a
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Fig. 4. Immunohistochemistry of the pancreas of the transgenic mouse. (A) Immunohistochemistry of a section of pancreas from
4-month-old transgenic (TG) and normal (N) mice using anti-insulin antibody (100U). In the transgenic mouse, insulin-positive cells
were observed in the core of the small islets. In addition, immunoreactive insulin was observed in some acinar cells (arrowhead) and
in epithelial cells of the pancreatic duct (arrow). (B) Immunohistochemistry of a section of pancreatic duct from 4-month-old trans-
genic (TG) and normal (N) mice using anti-glucagon antibody (400U). Note that immunoreactive glucagon was detected in the ductal
cells of the transgenic but not the normal mouse.
Table 1
Changes in plasma glucose concentration before and after intraperitoneal administration of glucose
Plasma glucose concentration (mM)
0 30 60 90 120 min
Normal (n = 6) 5.3 þ 0.6 8.3 þ 0.3 6.4 þ 0.3 6.9 þ 0.4 6.0 þ 0.6
Transgenic (n = 5) 5.2 þ 0.9 8.1 þ 0.6 7.5 þ 0.3 7.2 þ 0.4 5.5 þ 0.5
Glucose (1 g/kg) was injected intraperitoneally and the plasma glucose concentration was measured at various times after the adminis-
tration of glucose. Values are the means þ S.E. for indicated numbers.
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CD68, a marker antigen of macrophage. They did
not express myoglobin, a marker of muscle cells,
either. Some of the abnormal endocrine cells also
expressed immunoreactive activin A (data not
shown). Additionally, cells containing immunoreac-
tive glucagon and activin A were also observed in the
core of some islets (Fig. 7). The shape of the cells
were irregular and they formed clusters. In the exo-
crine portion of the pancreas of the transgenic
mouse, most of the acini were morphologically nor-
mal. However, some of the exocrine portion was
morphologically abnormal. The area of abnormal
exocrine cells was 20.9 þ 4.8% (mean þ S.E., n = 10)
of the exocrine tissue. The shapes and the positions
of the cells were irregular and an acinar structure
was not organized. In normal acinar cells, zymogen
granules were observed in the center of the acinus
and basophilic ergastoplasm was distributed in the
basolateral side of the acinus (Fig. 8A). In the ab-
normal portion, the ergastoplasm was not observed
(Fig. 8C). Although the morphology was di¡erent
from normal acinar cells, they were positively stained
with anti-amylase antibody (Fig. 8D). In normal aci-
ni, immunoreactive amylase distributed in the apical
side of acini (Fig. 8B) whereas in abnormal exocrine
cells, immunoreactive amylase distributed di¡usely
(Fig. 8D). Despite of the histological abnormalities
in pancreatic islets, the urinary sugar was negative.
The plasma glucose concentrations before and after
an intraperitoneal administration of glucose in the
transgenic mouse was nearly identical to that of nor-
Fig. 5. Histological analysis of the atypical endocrine cells in
the pancreas of the transgenic mouse. HpE-stained section of
pancreas from a 4-month-old transgenic mouse. Note that mul-
tinuclear cells with various shapes were observed (arrows)
(A,B).
Fig. 6. Immunohistochemistry of the atypical endocrine cells.
Immunohistochemistry of adjacent sections of pancreas from a
4-month-old transgenic mouse using anti-insulin (A) and anti-
glucagon (B) antibodies.
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Fig. 7. Immunohistochemistry of the islet of the transgenic mouse. Immunohistochemistry of an islet from 4-month-old transgenic
(TG) and normal (N) mice using anti-glucagon (Glu) and anti-activin A (Act) antibodies.
Fig. 8. Immunohistochemistry of the pancreas of normal and transgenic mice. (A) HpE-stained section of pancreas of a 4-month-old
normal mouse (400U). Basophilic ergastoplasm was observed in the basolateral side of the acinar cells. (B) Immunohistochemistry of
pancreas of a normal mouse using anti-amylase antibody (400U). Amylase immunoreactivity was found in the luminal side of the aci-
nus. (C) HpE-stained section of pancreas of the transgenic mouse (400U). Basophilic ergastoplasm was not observed. (D) Immuno-
histochemistry of pancreas of a 4-month-old transgenic mouse using anti-amylase antibody. Amylase immunoreactivity was distributed
di¡usely in the cytoplasm.
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mal mouse (Table 1). The insulin response to glucose
in the transgenic mice was identical to that in normal
mice (Table 2). The insulin content of the pancreas in
the transgenic mice was identical to that in normal
mice (data not shown).
4. Discussion
In the present study, we established a transgenic
mouse line expressing tActRII under the control of
the L-actin promoter. The tActRII blocks the signal-
ing pathway activated by activins and related ligands
in a dominantly negative fashion [11,28]. The L-actin
promoter enables the expression of the transgene ef-
fectively in various tissues [29]. Yet, the expression
level of the transgene may vary depending upon the
cell types. Therefore, the blockade of the e¡ect of
activins may not be complete in some types of cells.
This may explain why some of the abnormalities de-
scribed in the mutant mice lacking L-subunits of ac-
tivin [14,15] were not observed in our transgenic
mice. In this regard, we have probably underesti-
mated the abnormalities caused by the blockade of
the activin action. Despite these limitations, the
present results provide some important information
concerning the physiological signi¢cance of activins
and related ligands in the development and di¡eren-
tiation of the pancreatic cells.
The transgenic mice expressing tActRII had vari-
ous abnormalities in pancreatic endocrine cells. Most
of the pancreatic islets were small in size and many
of them located along the pancreatic ducts. In addi-
tion, insulin-producing cells were found in the pan-
creatic duct and small acini located by the duct.
These observations were similar to the histological
¢ndings found in regenerating pancreas and suggest
that neogenesis of endocrine cells took place in the
transgenic mice. Presumably, di¡erentiation and/or
maturation of the islet endocrine cells may have
been attenuated in these mice and neogenesis of en-
docrine cells was promoted as a compensatory mech-
anism. Migration of the islets may have also been
inhibited to some extent since many islets were lo-
cated by the ducts. These results were in agreement
with a recent report by Yamaoka et al. [30]. They
showed that in transgenic mice expressing tActRII
under the control of the insulin promoter, pancreatic
islets were severely hypoplastic. In their transgenic
mice, glucose tolerance was impaired and the re-
sponse of insulin was signi¢cantly lower than that
in control mice. In contrast, glucose tolerance was
almost normal in our transgenic mice. The di¡erence
may be due at least partly to the di¡erence in the
expression levels of tActRII in L-cells since Yamaoka
et al. [30] used powerful insulin promoter and the
copy number was greater.
The most intriguing observation obtained in the
present study was that there were yet undescribed
abnormal endocrine cells in the pancreas. The shapes
of the endocrine cells were quite variable and their
sizes were sometimes greater than those of islets.
Morphologically, some of them appeared to be syn-
cytium and numerous nuclei were randomly clustered
in the cytoplasm. But since we did not examine them
by electron microscopy, we are not totally certain
whether or not these cells are de¢nitely syncytial
cells. In any event, these cells expressed both gluca-
gon and insulin and some of them also expressed
activin A. In the fetal mouse pancreas, endocrine
precursor cells ¢rst appeared on embryonic day 9
(E9) [31]. These precursors express both glucagon
and insulin [31^33]. We reported that in the fetal
rat pancreas, endocrine precursor cells ¢rst expressed
activin A [26]. Subsequently, cells expressing activin
A, insulin and glucagon were observed [26]. Hence,
the double- or triple-positive endocrine cells found in
the transgenic mice resemble the endocrine precursor
cells in the fetal pancreas. At present, the exact
mechanism for the formation of large and possibly
multinuclear cells is unknown. In this regard, our
(M.F., I.K.) unpublished observation indicated that
multinuclear cells extending multiple long processes
Table 2
Changes in plasma insulin concentration before and after intra-




Normal (n = 5) 126 þ 28 402 þ 39
Transgenic (n = 5) 103 þ 14 372 þ 45
Glucose was administered as for Table 1 and the plasma insulin
concentration was measured before and after 30 min of the ad-
ministration of glucose. Values are the mean þ S.E. for indicated
number.
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were observed in regenerating rat pancreas after 90%
pancreatectomy. Quite interestingly, these cells ex-
pressed immunoreactive insulin, glucagon and activin
A. The multinuclear cells found in the transgenic
mouse may be similar to the cells found in regener-
ating pancreas. Cells expressing insulin, glucagon
and activin A were also observed in the core of the
islets in the transgenic mice. In the fetal rat pancreas,
the triple-positive cells were found in the islets on
between E13.5 to E15 and they eventually disap-
peared [26]. The existence of the triple-positive cells
in the adult islets of the transgenic mice strongly
suggested that di¡erentiation of endocrine cells was
attenuated in the transgenic mice. Activin A may
have modulated di¡erentiation of the endocrine cells
in vivo as an autocrine factor [26]. It should be noted
that atypical endocrine cells were not observed in the
transgenic mice described by Yamaoka et al. [30].
The di¡erence may be due to the di¡erent promoters
used in two studies. We used the L-actin promoter
while Yamaoka et al. [30] used the insulin promoter.
It is expected that tActRII is expressed in endocrine
precursor cells in our transgenic mice whereas in the
transgenic mice developed by Yamaoka et al. [30],
tActRII may be expressed after endocrine cells are
committed to produce insulin.
In addition to the double- or triple-positive cells,
another type of abnormal cells were observed in the
exocrine portion of the transgenic mouse. They ex-
pressed amylase and, in fact, morphologically normal
acini were occasionally found among the clusters of
the abnormal cells. Although these cells expressed
amylase, they did not have the characteristics of po-
larized acinar cells. Di¡erentiation into acinar cells
was inhibited to some extent in these cells. Miralles
et al. [34] showed that coculture of embryonic mes-
enchyme is inhibitory for the formation of endocrine
cells in E12.5 rat pancreatic rudiment in culture. In-
terestingly, the addition of follistatin, an inhibitor of
the activin action, decreases the number of endocrine
cells and increases the number of amylase-containing
cells [34]. Their results suggest that blocking the ac-
tion of endogenous activin or related ligand leads to
the formation of exocrine cells. Thus, it would be
expected that cells tend to convert to exocrine lineage
if the activin action is blocked. The amylase-positive
cells found in the transgenic mouse might have been
transitional cells during the course of exocrine di¡er-
entiation. We have reported recently that activin A
converts amylase-secreting pancreatic AR42J cells
into endocrine cells [27]. The results suggest that ac-
tivin A mediates the commitment of amphicrine
AR42J cells to di¡erentiate into endocrine cells. In
the transgenic mouse, neogenesis of endocrine cells
took place. This observation, however, does not ex-
clude the possibility of the involvement of activin A
in the endocrine determination. If the commitment is
regulated by multiple factors including activin A,
then the inhibition of commitment in the transgenic
mouse would be only partial. Our unpublished ob-
servation indicates that TGF-L and bone morpho-
genic protein-4 (BMP-4) partially reproduces the ef-
fect of activin A under some conditions in AR42J
cells. In this regard, addition of TGF-L to the culture
of pancreatic rudiment inhibits the development of
acinar tissue and promotes the development of endo-
crine cells [35]. It is thus possible that endocrine de-
termination is regulated by multiple members of the
TGF-L superfamily. As the inhibition of the activin
action by follistatin leads to the formation of exo-
crine cells [34], the appearance of abnormally di¡er-
entiated exocrine cells suggests that di¡erentiation of
the precursor cells into endocrine lineage is attenu-
ated partially in the transgenic mouse. Bottinger et
al. [36] developed transgenic mice expressing trun-
cated type II TGF-L receptor. In these mice, severe
abnormalities were observed in exocrine portion of
the pancreas including ductular transformation, neo-
angiogenesis, ¢brosis and in¢ltration of macro-
phages. In addition, many of acinar cells expressed
proliferating cell nuclear antigen and the number of
apoptotic cells was increased. Normal di¡erentiation
and/or maintenance of di¡erentiated phenotype were
disrupted in these mice. Since abnormalities found in
these mice and transgenic mice expressing tActRII
are di¡erent, TGF-L and activin A exert di¡erent
e¡ects in the development of pancreatic exocrine tis-
sue.
The tActRII blocks the e¡ect of activins in a dom-
inantly negative fashion. In addition, the tActRII
probably inhibits the action of osteogenic protein-1/
BMP-7 (OP-1/BMP-7) since OP-1/BMP-7 also binds
to the type II activin receptor [37]. The mRNA for
OP-1/BMP-7 is expressed in the pancreas although
the exact site of expression is not yet known [38].
Therefore, we cannot rule out the possibility that
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the abnormalities found in the transgenic mice were
due at least partly to the inhibition of OP-1 action.
In any event, the present results suggest that activins
or related ligands may play an important role in the
di¡erentiation of both pancreatic endocrine and exo-
crine cells.
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